ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient-reported outcome measures"

  • Abstract Number: 431 • 2019 ACR/ARP Annual Meeting

    Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis

    Michiel Luijten 1, Caroline Terwee 2, Hedy van Oers 2, Mala Joosten 3, Merlijn van den Berg 2, Dieneke Schonenberg-Meinema 2, Koert Dolman 4, Rebecca Ten Cate 5, Leo Roorda 6, Martha Grootenhuis 3, Marion van Rossum7 and Lotte Haverman 2, 1Amsterdam University Medical Centers, Amsterdam, Noord-Holland, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands, 4Onze Lieve Vrouwe Gasthuis West, Amsterdam, Netherlands, 5Leiden University Medical Centre, Leiden, Netherlands, 6Amsterdam Rehabilitation Research Center | Reade, Amsterdam, Netherlands, 7Amsterdam University Medical Centers, Amsterdam

    Background/Purpose: Patient-reported outcome measures (PROMs) are often used to include the patients perspective on treatment (outcome). However, the choice of PROMs is difficult, as there…
  • Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting

    Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials

    Vibeke Strand1, Namita Tundia 2, Alan Friedman 3, Heidi Camp 2, Jessica Suboticki 4, Debbie Goldschmidt 5, Catherine Fernan 5 and Martin Bergman 6, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2AbbVie Inc., North Chicago, IL, 3AbbVie Inc., North Chicago, 4AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 5Analysis Group, Inc., New York, NY, 6Drexel University College of Medicine, Stockholm, Sweden

    Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
  • Abstract Number: 329 • 2018 ACR/ARHP Annual Meeting

    Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures

    Elisheva Weinberger1, Douglas Einstadter2 and Marina Magrey1, 1Rheumatology, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, 2Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH

    Background/Purpose:  “Treat to target” is the goal of therapy in the treatment of Rheumatoid Arthritis (RA) based on the 2015 American College of Rheumatology (ACR)…
  • Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting

    Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry

    Dimitrios A. Pappas1,2, Namita Tundia3, Ying Shan2, Heather J Litman2 and Joel Kremer4, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3AbbVie Inc., North Chicago, IL, 4Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
  • Abstract Number: 892 • 2018 ACR/ARHP Annual Meeting

    Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)

    Nicolas Richard1, Nigil Haroon2, George Tomlinson3, Ismail Sari1, Zahi Touma4 and Robert D Inman1, 1Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, 2Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: The Ankylosing Spondylitis Quality of Life (ASQoL) is a readable and simple to complete questionnaire relating to health-related quality of life (HRQoL) in subjects…
  • Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting

    Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients

    Jens Gert Kuipers1, Michael Koller2, Ulrich Rueffer3, Florian Zeman2, Karolina Mueller4 and Joachim Weis5, 1Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, 2Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 3German Fatigue Society, Cologne, Germany, 4Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 5University Clinic Centre Freiburg, Freiburg, Germany

    Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
  • Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting

    Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment

    Ana-Maria Orbai1, Jessica Walsh2, Peter Nash3, Lichen Teng4, Benoit Guerette4 and Rieke Alten5, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, 3University of Queensland, Brisbane, Australia, 4Celgene Corporation, Summit, NJ, 5Schlosspark-Klinik University Medicine, Berlin, Germany

    Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…
  • Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects

    Robert F. Spiera1, Laura K. Hummers2, Lorinda Chung3, Tracy M. Frech4, Robyn T. Domsic5, Vivien Hsu6, Daniel E. Furst7, Jessica K. Gordon1, Maureen D. Mayes8, Robert W. Simms9, Elizabeth Lee10, Scott Constantine10 and Barbara White10, 1Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, 7Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, 8Rheumatology, University of Texas McGovern Medical School, Houston, TX, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
  • Abstract Number: 2480 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group

    Richard Zogala1, Karla Criner2, Maria A. Lopez-Olivo1, Natalia Zamora3, Devesh Rai1, Gregory Pratt4, Jude K. A. des Bordes1, Robin Christensen5 and Maria Suarez-Almazor1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2Internal Medicine, Baylor College of Medicine, Houston, TX, 3Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 4Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 5Department of Rheumatology, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, & Department of Rheumatology, Odense University Hospital, Copenhagen, Denmark

    Background/Purpose: International registries and cohorts could potentially provide long-term data on patient-centered outcomes. In recent years there has been a concerted effort to define a…
  • Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting

    Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE

    Rebecca Heijke1, Mathilda Björk1, Martina Frodlund1, Laura McDonald2, Evo Alemao3 and Christopher Sjöwall1, 1Linköping University, Linköping, Sweden, 2Bristol-Myers Squibb, Uxbridge, United Kingdom, 3Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
  • Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials

    Vibeke Strand1, Rita Ganguly2, Nan Li3, Prasheen Agarwal3, Shihong Sheng3, Kaiyin Fei3, Kelly McQuarrie3 and Sharon Popik3, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2GlaxoSmithKline, Collegeville, PA, 3Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases.  Effects of sirukumab on RA symptoms…
  • Abstract Number: 2242 • 2017 ACR/ARHP Annual Meeting

    Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China

    Rong Mu1, Jing Yang2, Hua Wei3, Wenqiang Fan4, Jianlin Huang5, Hongzhi Wang6, Jinli Ru7, Yongfu Wang8, Jinmei Zou2, Jianling Dong2, Xinwang Duan9, Fang He10, Xiaofei Shi11, Xiafei Xin12, Fei Xiao13, Hui Xiao13, Yuhua Jia13, Minjun Wang13, Lijun He13, Rui Bai13, Xiyao Huang13, Bing Wu13 and Zhanguo Li14, 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 2Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, 3No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, 4Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, 5Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, 6The First Hospital of Jiaxing, Jiaxing, China, 7The 264th Hospital of the PLA, Taiyuan, China, 8The First Affiliated Hospital of BaoTou Medical College, Baotou, China, 9Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, 10Central Hospital of Sui Ning, Sichuan, Suining, China, 11The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, 12Ningbo First Hospital, Zhejiang, Ningbo, China, 13Gothic Internet Technology Corporation, Shanghai, China, 14Rheum/Immunology, Peking University People's Hospital, Beijing, China

    Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 lower than 2.6 (remission) or below 3.2 (low disease activity), is the main management strategy. The Smart System of…
  • Abstract Number: 2884 • 2017 ACR/ARHP Annual Meeting

    A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis

    Robert F. Spiera1, Laura K. Hummers2, Lorinda Chung3, Tracy M. Frech4, Robyn T. Domsic5, Vivien Hsu6, Daniel E. Furst7, Jessica K. Gordon1, Maureen D. Mayes8, Robert W. Simms9, Scott Constantine10 and Barbara White10, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, 3Rheumatology, Stanford University Medical Center, Palo Alto, CA, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, 7David Geffen School of Medicine at UCLA, Los Angeles, CA, 8University of Texas McGovern Medical School, Houston, TX, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Systemic sclerosis (SSc) is characterized in part by chronic activation of the innate immune system with fibrosis.  Anabasum is a non-immunosuppressive, synthetic, orally administered…
  • Abstract Number: 2953 • 2017 ACR/ARHP Annual Meeting

    Drivers of Satisfaction with Care in Lupus 

    Bhavika Sethi1, Ailda Nika2, Winston Sequeira3, Joel A. Block4, Sergio Toloza5, Ana Bertoli6, Ivana Blazevic7, Luis M. Vilá8, Ioana Moldovan9, Karina Torralba10, Davide Mazzoni11, Elvira Cicognani11, Sarfaraz Hasni12, Berna Goker13, Seminur Haznedaroglu13, Josiane Bourré-Tessier14, Sandra V. Navarra15, Chi Chiu Mok16, Ann Clarke17, Michael Weisman18, Daniel J. Wallace19 and Meenakshi Jolly3, 1University of Birmingham, Birmingham, United Kingdom, 2Rheumatology, Rush University Medical Center, Chicago, IL, 3Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, 4Division of Rheumatology, Rush University Medical Center, Chicago, IL, 5Rheumatology, Hospital San Juan Batista, Catamarca, Argentina, Catamarca, Argentina, 6Instituto Reumatológico Strusberg, Córdoba, Argentina, 7Rheumatology, Universidad de Buenos Aires, Buenos Aires, Argentina, 8Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, 9Rheumatology, Beaver Medical Group, Redlands, CA, 10Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, 11Department of Psychology, University of Bologna, Bologna, Italy, 12National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 13Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, 14Rheumatology, University of Montreal, Montreal, QC, Canada, 15Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, 16Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 17Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 18Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, 19Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA

    Background/Purpose: Although survival in SLE has improved, quality of life (QOL) remains poor. Physicians aim to reduce suffering and improve health outcomes, while maximizing efficiency…
  • Abstract Number: 236 • 2017 ACR/ARHP Annual Meeting

    Are Magnetic Resonance Imaging Features of the Hand Associated with Patient Reported Physical Function, Global Assessment of Disease Activity, Pain and Health Related Quality of Life in Rheumatoid Arthritis in Clinical Remission? – Longitudinal Results from an Observational Cohort

    Daniel Glinatsi1, Cecilie Heegaard Brahe2, Merete Lund Hetland1,3,4, Lykke Ørnbjerg1, Simon Krabbe5, Joshua Baker6, Mikael Boesen7, Zoreh Rastiemadabadi8, Lone Morsel-Carlsen8,9, Henrik Rogind1,3, Hanne Slott Jensen10, Annette Hansen11, Jesper Nørregaard12, Søren Jacobsen3,13, Lene Terslev1, Tuan Huynh12, Natalia Manilo14, Dorte Vendelbo Jensen1,15, Jakob M. Møller16, Niels Steen Krogh15 and Mikkel Østergaard1,3,17, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, 3University of Copenhagen, Copenhagen, Denmark, 4The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 5Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 6Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 7Department of Radiology and the Parker institute, Copenhagen University Hospital Frederiksberg, Copenhagen, Denmark, 8Department of Radiology, Copenhagen University Hospital Frederiksberg, Copenhagen, Denmark, 9Department of Radiology, Rigshospitalet, Copenhagen, Denmark, 10Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Frederiksberg, Denmark, Copenhagen, Denmark, 11Department of Rheumatology, Copenhagen University Hospital Gentofte, Copenhagen, Denmark, 12Center for Rheumatology and Spine Diseases, Nordsjællands Hospital, Hillerød, Denmark, 13Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 14Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Frederiksberg, Copenhagen, Denmark, 15The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 16Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, 17Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: To assess whether magnetic resonance imaging (MRI) inflammation and damage in the wrist and hand of rheumatoid arthritis (RA) patients are associated with patient-reported…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology